Although the mechanisms by which HELLS contributes to RB tumorigenesis still remain unclear, HELLS may be considered as a potential therapeutic target highly selective for RB cells as it is not expressed in terminally differentiated retinal cells and its inhibition does not affect normal retinal development. This evidence concerns the gene HELLS and retinoblastoma.